These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 15318940)

  • 1. Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status.
    Madrid MA; Lo RW
    Breast Cancer Res; 2004; 6(5):R593-600. PubMed ID: 15318940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
    Akhdar A; Bronsard M; Lemieux R; Geha S
    Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromogenic in situ hybridization analysis of HER-2/neu status in cytological samples of breast carcinoma.
    Kim GY; Oh YL
    Cytopathology; 2004 Dec; 15(6):315-20. PubMed ID: 15606364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.
    Tanner M; Gancberg D; Di Leo A; Larsimont D; Rouas G; Piccart MJ; Isola J
    Am J Pathol; 2000 Nov; 157(5):1467-72. PubMed ID: 11073807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER 2 status in invasive breast cancer: immunohistochemistry, fluorescence in-situ hybridization and chromogenic in-situ hybridization.
    Shirsat HS; Epari S; Shet T; Bagal R; Hawaldar R; Desai SB
    Indian J Pathol Microbiol; 2012; 55(2):175-9. PubMed ID: 22771638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between immunohistochemistry and chromogenic in situ hybridization in assessing HER-2 status in breast cancer.
    Todorović-Raković N; Jovanović D; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
    Pathol Int; 2005 Jun; 55(6):318-23. PubMed ID: 15943788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases.
    Sáez A; Andreu FJ; Seguí MA; Baré ML; Fernández S; Dinarés C; Rey M
    Breast; 2006 Aug; 15(4):519-27. PubMed ID: 16290155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.
    Ridolfi RL; Jamehdor MR; Arber JM
    Mod Pathol; 2000 Aug; 13(8):866-73. PubMed ID: 10955453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era.
    Vocaturo A; Novelli F; Benevolo M; Piperno G; Marandino F; Cianciulli AM; Merola R; Donnorso RP; Sperduti I; Buglioni S; Mottolese M
    Oncologist; 2006 Sep; 11(8):878-86. PubMed ID: 16951391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
    Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
    Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer.
    Hyun CL; Lee HE; Kim KS; Kim SW; Kim JH; Choe G; Park SY
    J Clin Pathol; 2008 Mar; 61(3):317-21. PubMed ID: 17761736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
    Zhao J; Wu R; Au A; Marquez A; Yu Y; Shi Z
    Mod Pathol; 2002 Jun; 15(6):657-65. PubMed ID: 12065780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization.
    Isola J; Tanner M; Forsyth A; Cooke TG; Watters AD; Bartlett JM
    Clin Cancer Res; 2004 Jul; 10(14):4793-8. PubMed ID: 15269154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?
    Bhargava R; Lal P; Chen B
    Am J Clin Pathol; 2005 Feb; 123(2):237-43. PubMed ID: 15842048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
    Prati R; Apple SK; He J; Gornbein JA; Chang HR
    Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.
    Thomson TA; Hayes MM; Spinelli JJ; Hilland E; Sawrenko C; Phillips D; Dupuis B; Parker RL
    Mod Pathol; 2001 Nov; 14(11):1079-86. PubMed ID: 11706067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma.
    Sartelet H; Lagonotte E; Lorenzato M; Duval I; Lechki C; Rigaud C; Cucherousset J; Durlach A; Graesslin O; Abboud P; Doco-Fenzy M; Quereux C; Costa B; Polette M; Munck JN; Birembaut P
    J Clin Pathol; 2005 Aug; 58(8):864-71. PubMed ID: 16049291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer].
    Zhang GH; Shi DR; Liang XM; Hou JH; Kang SY; Zhu WD; Li XB; Shao Y; Chen LR; Zhou Y
    Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):580-3. PubMed ID: 17134562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of her-2/neu by chromogenic in situ hybridization on borderline (2+) immunohistochemistry cases in carcinoma breast.
    Asif M; Khadim MT; Mushtaq S; Mamoon N; Akhtar F; Ali Z
    Asian Pac J Cancer Prev; 2011; 12(1):211-4. PubMed ID: 21517259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER-2 DNA quantification of paraffin-embedded breast carcinomas with LightCycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridization.
    Ntoulia M; Kaklamanis L; Valavanis C; Kafousi M; Stathopoulos E; Arapantoni P; Mavroudis D; Georgoulias V; Lianidou ES
    Clin Biochem; 2006 Sep; 39(9):942-6. PubMed ID: 16916505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.